Tags

Type your tag names separated by a space and hit enter

Successful Treatment of Immune Thrombocytopenic Purpura with Intracranial Hemorrhaging and Duodenal Bleeding Following SARS-CoV-2 Vaccination.
Intern Med. 2022 Jun 15; 61(12):1891-1895.IM

Abstract

Several vaccines have been developed for coronavirus disease 2019 - caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - in record time. A few cases of immune thrombocytopenic purpura (ITP) following SARS-CoV-2 vaccination have been reported. We herein report a 90-year-old man who received the Pfizer-BioNTech SARS-CoV-2 vaccine (BNT162b2) and developed severe thrombocytopenia with intracranial hemorrhaging and duodenal bleeding, consistent with vaccine-related ITP. He was successfully treated with intravenous immunoglobulin, prednisolone, and eltrombopag and discharged without cytopenia. Vaccine-related ITP should be suspected in patients presenting with abnormal bleeding or purpura after vaccination.

Authors+Show Affiliations

Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Japan.Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Japan.Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Japan.Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Japan.

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

35400701

Citation

Baba, Yuta, et al. "Successful Treatment of Immune Thrombocytopenic Purpura With Intracranial Hemorrhaging and Duodenal Bleeding Following SARS-CoV-2 Vaccination." Internal Medicine (Tokyo, Japan), vol. 61, no. 12, 2022, pp. 1891-1895.
Baba Y, Sakai H, Kabasawa N, et al. Successful Treatment of Immune Thrombocytopenic Purpura with Intracranial Hemorrhaging and Duodenal Bleeding Following SARS-CoV-2 Vaccination. Intern Med. 2022;61(12):1891-1895.
Baba, Y., Sakai, H., Kabasawa, N., & Harada, H. (2022). Successful Treatment of Immune Thrombocytopenic Purpura with Intracranial Hemorrhaging and Duodenal Bleeding Following SARS-CoV-2 Vaccination. Internal Medicine (Tokyo, Japan), 61(12), 1891-1895. https://doi.org/10.2169/internalmedicine.9199-21
Baba Y, et al. Successful Treatment of Immune Thrombocytopenic Purpura With Intracranial Hemorrhaging and Duodenal Bleeding Following SARS-CoV-2 Vaccination. Intern Med. 2022 Jun 15;61(12):1891-1895. PubMed PMID: 35400701.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Successful Treatment of Immune Thrombocytopenic Purpura with Intracranial Hemorrhaging and Duodenal Bleeding Following SARS-CoV-2 Vaccination. AU - Baba,Yuta, AU - Sakai,Hirotaka, AU - Kabasawa,Nobuyuki, AU - Harada,Hiroshi, Y1 - 2022/04/09/ PY - 2022/4/12/pubmed PY - 2022/6/18/medline PY - 2022/4/11/entrez KW - SARS-CoV-2 vaccine KW - bleeding KW - immune thrombocytopenic purpura SP - 1891 EP - 1895 JF - Internal medicine (Tokyo, Japan) JO - Intern Med VL - 61 IS - 12 N2 - Several vaccines have been developed for coronavirus disease 2019 - caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - in record time. A few cases of immune thrombocytopenic purpura (ITP) following SARS-CoV-2 vaccination have been reported. We herein report a 90-year-old man who received the Pfizer-BioNTech SARS-CoV-2 vaccine (BNT162b2) and developed severe thrombocytopenia with intracranial hemorrhaging and duodenal bleeding, consistent with vaccine-related ITP. He was successfully treated with intravenous immunoglobulin, prednisolone, and eltrombopag and discharged without cytopenia. Vaccine-related ITP should be suspected in patients presenting with abnormal bleeding or purpura after vaccination. SN - 1349-7235 UR - https://www.unboundmedicine.com/medline/citation/35400701/Successful_Treatment_of_Immune_Thrombocytopenic_Purpura_with_Intracranial_Hemorrhaging_and_Duodenal_Bleeding_Following_SARS_CoV_2_Vaccination_ DB - PRIME DP - Unbound Medicine ER -